Browsing by Author "Rivas Tafurt, Giovanna Patricia"
Now showing 1 - 5 of 5
Results Per Page
Sort Options
Item A Vitiligo-like Cutaneous Reaction Induced by Ribociclib in Advanced Breast Cancer: An Unusual Case Report from Colombia(Multidisciplinary Digital Publishing Institute (MDPI), 2025-05-19) Montenegro, John Fernando; Rivas Tafurt, Giovanna Patricia; Vidal Cañas, Sinthia; Diaz Diaz, Miguel Ángel; Bermudez, Cesar Eduardo; Florez, Daniel; Bravo Gustin, Andres Felipe; Liscano, YamilBackground: Cutaneous toxicities associated with CDK4/6 inhibitors are uncommon but may affect treatment adherence. We present the case of a patient with advanced breast cancer who developed vitiligo-like lesions after initiating ribociclib, contributing to the growing evidence of this under-recognized adverse effect. Methods: We present the case of a 72-year-old woman diagnosed in 2007 with early-stage, luminal A, HER2-negative breast cancer, initially treated with surgery and tamoxifen. In 2022, she experienced locoregional recurrence with bone metastases. In January 2023, she began treatment with ribociclib plus letrozole. Two months later, she developed intense pruritus, xerosis, and paresthesia, followed by hypopigmented lesions on her face and upper extremities. Clinical evaluation, supported by photographs and a skin biopsy (led to a diagnosis of ribociclib-induced vitiligo. Management included dose adjustments to the ribociclib and dermatologic treatments, including topical corticosteroids, antihistamines, and short courses of oral prednisone. Results: By September 2024, her skin lesions had stabilized and her pruritus improved with a reduced dose of ribociclib (one tablet per day). However, the hypopigmented patches persisted, mainly on her face and extremities. Despite these cutaneous effects, she maintained an acceptable quality of life and continued effective oncologic treatment.Item Autoimmune Hemolytic Anemia Caused by Cold Agglutinin Antibodies in Systemic Lupus erythematosus—a Rare Association: Case Report(Dove Medical Press Ltd, 2023-09-04) Osorio Toro, Luis Miguel; Quintana Ospina, Jhon Herney; Melo Burbano, Luis Álvaro; Ruiz Jiménez, Paola Andrea; Daza Arana, Jorge Enrique; Rivas Tafurt, Giovanna Patricia; Izquierdo Loaiza, Jorge HernánAutoimmune hemolytic anemias (AIHAs) are rare and heterogeneous disorders characterized by the destruction of redblood cells by warm or cold antibodies. Hemolytic anemia associated with warm antibodies is the most common, whereas coldantibodies are rare and infrequent in cases published in the scientific literature. Herein, we present the case of a young patient withsystemic lupus erythematosus (SLE) and autoimmune hemolytic anemia caused by cold antibodies. Initially, infectious etiology andhematological malignancy were considered, which were ruled out. She required management in the intensive care unit due to severehematological involvement and responded well to immunomodulatory therapy. This case illustrates the importance of a strong clinicalsuspicion of AIHA due to cold agglutinins associated with SLE when faced with similar clinical symptoms in order to achieve a timelydiagnosis and provide optimal therapy.Item First case report of tumor lysis syndrome after third line systemic therapy with gemcitabine and pazopanib in a patient with lower extremity soft tissue sarcoma(AME Publishing Company, 2023-12-31) Benitez Escobar, Edith Norela; Galindes Casanova, Duvan Arley; Melo Burbano, Luis Álvaro; Bonilla Bonilla, Diana Marcela; Osorio Toro, Luis Miguel; Daza Arana, Jorge Enrique; Escobar Dávila, Santiago Leandro; Rivas Tafurt, Giovanna PatriciaBackground: Anaplastic lymphoma kinase (ALK) rearrangement generates an oncogenic ALK tyrosine kinase that activates numerous downstream signaling pathways, leading to increased cell proliferation and survival. About 5% of non-small cell lung cancer (NSCLC) patients are being diagnosed with tumor harboring ALK-positive. ALK rearrangement is an important molecular target for the treatment of NSCLC, and alectinib is a potent and highly selective second-generation ALK inhibitor. Alectinib as a neoadjuvant therapy has been reported in previous studies. However, cases of patients undergoing left total pulmonary resection after neoadjuvant therapy are rare. Case Description: In this report, a 52-year-old Asian woman’s chest computed tomography (CT) showed mass shadows in the left lung. Echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) fusion variant was detected by next-generation sequencing. We administered the targeted drug alectinib at 600 mg twice daily for two and a half months. Positron emission tomography (PET)-CT examination showed that the left lung mass and lymph nodes were significantly reduced. The tumor node metastasis (TNM) stage was reduced from cT4N2M0, IIIb to ycT2aN0M0, IB. Then she underwent thoracoscopic transthoracotomy of the left total lung. Oral alectinib therapy was continued after surgery, and the follow-up duration was one yearItem Oxaliplatin-Associated Takotsubo Cardiomyopathy in a Patient with Metastatic Gastric Cancer: A Case Report(2023-08-14) Osorio Toro, Luis Miguel; Bonilla Bonilla, Diana Marcela; Escobar Dávila, Santiago Leandro; Quintana Ospina, Jhon Herney; Melo Burbano, Luis Alvaro; Benitez Escobar, Edith Norela; Galindes Casanova, Duván Arley; Daza Arana, Jorge Enrique; Rivas Tafurt, Giovanna PatriciaWe present the case of a 64-year-old female with stage IV gastric adenocarcinoma, pulmonary, and abdominal wall metastases, and no history of cardiovascular disease. In palliative care, she received systemic cytotoxic treatment with fluorouracil, leucovorin, oxaliplatin, and docetaxel protocol, which was well tolerated over five cycles. During cycle 6, she presented with cardiovascular symptoms with hemodynamic consequences while receiving oxaliplatin injection without docetaxel or 5-fluorouracil. She was transferred to the emergency department and then to the intensive care unit. She developed no complications during the hospital stay and was discharged after 10 days with preserved systolic function and no structural changes at the myocardial level. The electrocardiogram, echocardiogram, cardiac catheterization, and magnetic resonance imaging findings indicated an oxaliplatin-associated Takotsubo syndrome. The immunochemistry analysis showed PD-L1 expression level TPS: 40% and the foundation one genomic profiling revealed high mutation load, microsatellite instability, and HER2 not found. The patient is currently asymptomatic and on pembrolizumab monotherapy with good tolerance and partial treatment response.Item Report of Henoch-Schönlein purpura associated with trastuzumab emtansine(ecancer Global Foundation, 2024) Escobar Dávila, Santiago Leandro; Rivas Tafurt, Giovanna Patricia; Melo Burbano, Luis Álvaro; Osorio Toro, Luis Miguel; Benítez Escobar, Edith Norela; Galindes Casanova, Duván Arley; Izquierdo Loaiza, Jorge Hernán; Cárdenas Perilla, Rodrigo Andrés; Orozco De la Hoz, CarlosVasculitides are a set of pathologies that can affect one or several organs, in the short and long term. They are associated with various etiologies, among which paraneoplastic syndromes and medications stand out. Although everyday cancer therapies are more directed against a therapeutic target, their use can cause a wide spectrum of complications. Some treatments against human epidermal growth factor 2 (HER2) have been associated with cutaneous and pulmonary vasculitis. We present the first case of Henoch-Schönlein purpura associated with the use of T-DM1 in a patient with HER2 breast cancer.